Motus GI Holdings, Inc.

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Motus GI Holdings, Inc. - overview

Established

2010

Location

Lauderdale, FL, US

Primary Industry

Medical Devices & Equipment

About

Motus GI Holdings, Inc. specializes in developing innovative solutions for gastrointestinal procedures, enhancing colonoscopy outcomes through its advanced Pure-Vu EVS System. Motus GI Holdings, Inc. was founded in 2010 in Lauderdale, US, focusing on improving gastrointestinal procedures.


The company has undergone strategic changes to enhance its product offerings. It has raised a total of USD 3. 50 mn through its most recent funding round, a Private Placement/Follow on in March 2022, which completed its total fundraising efforts of USD 3. 50 mn since inception.


The company is led by CEOs Mark Pomeranz and Tim Moran, who have extensive experience in the medical technology sector, guiding the firm's growth and operational strategies. Motus GI Holdings, Inc. focuses on enhancing the outcomes of gastrointestinal procedures through its flagship product, the Pure-Vu EVS System. This system improves colonoscopy quality by providing a mechanism to clear the colonic view during examinations, facilitating better visualization and diagnostic accuracy.


The Pure-Vu EVS System includes components like the Flex Channel attachment and Workstation connection, streamlining clinical setups. Healthcare professionals, primarily gastroenterologists and nurses, are the primary users of this technology, with the company marketing its solutions mainly in North America and Europe. In the most recent year, 2022, Motus GI Holdings, Inc. reported revenue of USD 592,000 and an EBITDA of USD -16,684,000.


The company generates its revenue through sales of the Pure-Vu EVS System and associated consumables, either via direct sales or agreements with healthcare facilities, aligning its pricing strategy with the specific needs of healthcare providers, thus positioning its product as a premium offering in the market. Motus GI Holdings, Inc. plans to utilize the recent funding of USD 3. 50 mn to support clinical trial initiatives aimed at expanding the indications of the Pure-Vu system in colonoscopy for patients who struggle with traditional laxatives.


The company is also working on new product developments to enhance its offerings further. Motus GI is targeting expansion into new markets and regions, focusing on increasing its presence in North America and Europe to improve accessibility to its innovative solutions.


Current Investors

Ascent Biomedical Ventures, Orchestra Medical Ventures, Jacobs Investments

Primary Industry

Medical Devices & Equipment

Sub Industries

Biotechnology, Monitoring Equipment, Medical Software

Website

www.motusgi.com

Company Stage

Mature

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.